Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX319 vs EU-Phesgo in Chinese Healthy Male Subjects
NCT07495930Phase 1Not yet recruiting
- Sponsor
- Henlius
- Start
- Apr 2026
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HLX319 in breast cancer (2 arms), sponsored by Henlius. Primary endpoints: Area Under the Curve from Time Zero to Infinity up to 85 days and Maximum Observed Concentration up to 85 days. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
HLX319
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07495930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07495930.